Workflow
左甲状腺素钠片
icon
Search documents
福元医药: 北京福元医药股份有限公司关于左甲状腺素钠片获得药品注册证书的公告
Zheng Quan Zhi Xing· 2025-08-26 16:13
Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Levothyroxine Sodium Tablets, which will enhance the company's product line and market competitiveness [1][3]. Group 1: Drug Registration Details - The drug is named Levothyroxine Sodium Tablets, with a specification of 100μg [1]. - The drug is classified as a prescription drug and falls under the category of chemical drugs [1]. - The registration certificate was issued by the National Medical Products Administration, confirming that the drug meets the necessary registration requirements [1]. Group 2: Drug Development and Market Information - Levothyroxine Sodium Tablets were developed by Merck and were first approved for sale in France in June 1980 [2]. - The drug was approved for sale in China in July 1997 for various therapeutic uses, including treatment of non-toxic goiter and hypothyroidism [2]. - As of the announcement date, the company has invested a total of RMB 7.57 million in the research and development of this drug [2]. Group 3: Market Status of Similar Drugs - According to data from Minet, the sales revenue of Levothyroxine Sodium Tablets in China for 2024 is approximately RMB 1.14631 billion [2]. - The sales distribution includes RMB 758.17 million from urban public hospitals and county-level public hospitals, RMB 109.20 million from urban community centers and township health centers, and RMB 279.94 million from urban pharmacies and online pharmacies [2].
福元医药:关于左甲状腺素钠片获得药品注册证书的公告
Core Viewpoint - The announcement indicates that Fuyuan Pharmaceutical has received the drug registration certificate for Levothyroxine Sodium Tablets, allowing the company to commence production of the drug [1] Company Summary - Fuyuan Pharmaceutical has been granted a drug registration certificate by the National Medical Products Administration for Levothyroxine Sodium Tablets, with a specification of 100μg [1]
福元医药:“左甲状腺素钠片”取得注册证
Mei Ri Jing Ji Xin Wen· 2025-08-26 08:43
Company Summary - Fuyuan Pharmaceutical received the drug registration certificate for Levothyroxine Sodium Tablets from the National Medical Products Administration, allowing the production of this medication [1] - For the fiscal year 2024, Fuyuan Pharmaceutical's revenue composition is as follows: 93.12% from pharmaceutical preparations, 6.46% from medical devices, 0.36% from other businesses, and 0.06% from other sources [1] - The current market capitalization of Fuyuan Pharmaceutical is 12.4 billion yuan [1] Industry Summary - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]
福元医药(601089.SH):左甲状腺素钠片获得药品注册证书
Ge Long Hui A P P· 2025-08-26 08:27
Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received a drug registration certificate from the National Medical Products Administration for Levothyroxine Sodium Tablets (100μg), allowing the production of this medication [1] Group 1: Product Approval - The Levothyroxine Sodium Tablets were developed by Merck and were first approved for sale in France in June 1980 [1] - The drug was approved for domestic sale in China in July 1997 by the National Medical Products Administration [1] Group 2: Indications - Levothyroxine Sodium Tablets are indicated for the treatment of non-toxic goiter (with normal thyroid function) [1] - The medication is used to prevent the recurrence of goiter after thyroidectomy [1] - It serves as a replacement therapy for hypothyroidism [1] - The drug is also an adjunct treatment for hyperthyroidism when using antithyroid medications [1] - It is indicated for suppression therapy after thyroid cancer surgery [1] - The tablets are used in thyroid suppression tests [1]
福元医药:左甲状腺素钠片获得药品注册证书
Xin Lang Cai Jing· 2025-08-26 08:13
Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Levothyroxine Sodium Tablets, indicating approval for production [1] Group 1 - The Levothyroxine Sodium Tablets are approved in a specification of 100μg (based on Levothyroxine Sodium) [1] - The drug was developed by Merck and was first approved for marketing in France in June 1980 [1] - The company received the acceptance notice for the application on March 27, 2024, and has invested a total of RMB 7.57 million in research and development for this drug as of the announcement date (unaudited) [1]